This
deal would prove to be fruitful for Pfizer because Actavis has a sound back up
when it comes to the pharmaceutical business. The company boasts of a great and
diversified portfolio comprising of generic medicines and also some other
popular brands and few medicines that have recently been approved. This would
result in great benefits for Pfizer as buying Actavis would add to their
currently working products unit; this would further add new products to the
portfolio of Pfizer which is in desperate need to some strategizing and
assistance at the moment. Moreover Pfizer if it acquires Actavis they can shift
their domicile to Dublin which can further result in potential benefits.
The
company has not come upfront itself to speak on this topic. They have not yet clearly stated that they
are opting for Actavis, AstraZeneca or any other option that comes their way.
Joan Campion who is the spokesperson for Pfizer stated that, "evaluate all
opportunities, regardless of size, through the lens of value creation for our
shareholders and enhancing the competitiveness of our business.” Moreover other
analysts and media reports have also listed down few other companies that can
be a good option for Pfizer such as GlaxoSmithKline. Even Pfizer might opt for
buying Allegan.
These
deals might prove to be extremely fruitful for Pfizer stock since they have
been struggling for a fairly long time and now need to come with something that
would result as a game changer for them. Buying on a stable pharmaceutical
might be just the right thing that needs to be done in order to give it the
boost it needs. Pfizer is apparently doing the right thing by not focusing on
one company as keeping options open will result in benefits in terms of making
the right choice.
Hence
in a nutshell, Pfizer will soon emerge out of all its miseries if it buys the
right company which would not only add to their portfolio but assist it in
sailing swiftly to the shore.
0 comments:
Post a Comment